Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.84 |
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | C1R | P00736 | 7/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | C1S | P09871 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.49 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5975597 | 0.92 | KMT2A (1.00) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL10819490 | 0.91 | KMT2A (0.88) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL9528544 | 0.90 | KMT2A (0.86) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5975754 | 0.89 | KMT2A (0.84) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL9528246 | 0.89 | MAPT (1.00) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL9527940 | 0.86 | KMT2A (0.79) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL7185309 | 0.86 | KMT2A (0.79) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2314299 | 0.85 | KMT2A (1.00) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL30183217 | 0.85 | KMT2A (1.00) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL8524818 | 0.82 | MAPT (0.68) | MAPTGAAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | claimed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | MAPT 2054/4885GAA 1036/4885KMT2A 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.